Infant Bacterial Therapeutics AB (publ) Current Assets

As of the most recent data (June 2026), IBT-B.ST shows a current assets of $110M. That compares with $180M in the prior-year period — down 39.1% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, IBT-B.ST's current assets is now $110M (was $180M) — a 39.1% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Infant Bacterial Therapeutics AB (publ) is outperforming or lagging.

Tracking IBT-B.ST's current assets over time shows whether Infant Bacterial Therapeutics AB (publ) is scaling, shrinking, or reshaping that part of the business. The current reading is $110M That compares with $180M in the prior-year period — down 39.1% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this current assets page, Stockcircle has Infant Bacterial Therapeutics AB (publ)'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect current assets (currently $110M) with ownership activity and broader fundamentals.

Infant Bacterial Therapeutics AB (publ)'s current assets is $110M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.